Aethlon Medical (AEMD) FDA Approvals $5.08 +0.07 (+1.40%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$4.96 -0.12 (-2.26%) As of 09:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings Aethlon Medical's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Aethlon Medical (AEMD). Over the past two years, Aethlon Medical has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Hemopurifier. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Hemopurifier FDA Regulatory Timeline and Events Hemopurifier is a drug developed by Aethlon Medical for the following indication: Severe COVID-19. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Publication - June 26,2026Publication Drug: HemopurifierAnnounced Date: June 26, 2026Indication: Severe COVID-19AnnouncementAethlon Medical, Inc. announced publication of new peer-reviewed research in the International Journal of Molecular Sciences demonstrating that patients with Long COVID exhibit significantly increased levels of mannosylated extracellular vesicles (EVs) that can be captured using the same Galanthus nivalis agglutinin (GNA) affinity resin incorporated into the Company's Hemopurifier®.AI SummaryAethlon Medical said a new peer-reviewed study in the International Journal of Molecular Sciences adds scientific support for studying its Hemopurifier® in Long COVID. The research, done with investigators at the University of California, San Francisco, found that people with Long COVID have higher levels of altered extracellular vesicles, or EVs, in their blood. These EVs are tiny particles that can carry harmful material linked to disease. The company said the study showed these EVs are significantly mannosylated, meaning they display sugar patterns that can be targeted by Galanthus nivalis agglutinin, or GNA. That is important because the Hemopurifier uses the same GNA affinity resin to capture certain EVs and other disease-related particles. Aethlon said this creates a stronger scientific case for testing whether the device can remove harmful EVs and their cargo in Long COVID.Read AnnouncementProvided Update - October 7,2025Provided Update Drug: HemopurifierAnnounced Date: October 7, 2025Indication: Severe COVID-19AnnouncementAethlon Medical, Inc today provided observations on the preliminary changes in extracellular vesicle (EV), microRNA and lymphocyte counts in the first patient cohort in its ongoing oncology clinical trial in Australia.AI SummaryAethlon Medical shared early observations from the first three patients in its ongoing Australian oncology trial using the Hemopurifier. After one four-hour treatment, two of the three patients showed decreases in large extracellular vesicles (EVs), including platelet-derived EVs. All three patients had drops in EVs carrying PD-L1, which can block T cells. In two patients, levels of seven out of ten cancer-related microRNAs fell temporarily, returning to baseline within one to three weeks. Blood tests also showed improved immune ratios, such as neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios, in at least two participants. Total T cell counts rose, including CD4, CD8 and tumor-specific (CD137+) cells, although timing varied. The company cautioned that these results are based on just three patients, one of whom withdrew after one week, involve only a single treatment, and use descriptive statistics. It is too early to know if these changes will recur with more treatments or lead to clinical benefits.Read AnnouncementAbstract Presentation - June 9,2025Abstract Presentation Drug: HemopurifierAnnounced Date: June 9, 2025Indication: Severe COVID-19AnnouncementAethlon Medical, Inc announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel & Spa, Santa Fe, NM, United States, August 10-13,2025AI SummaryAethlon Medical, Inc. announced that an abstract on its Hemopurifier® Affinity Resin will be presented as a poster at the upcoming Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes. The event is scheduled to take place at the Eldorado Hotel & Spa in Santa Fe, NM, from August 10 to 13, 2025. The poster reviews the device’s ability to bind extracellular vesicles in blood samples from individuals suffering from long COVID, a condition with persistent symptoms following acute COVID-19. By using a proprietary lectin-based technology that targets mannosylated markers, the Hemopurifier® aims to remove these vesicles, which may contribute to ongoing health challenges. The presentation, set for August 12, 2025, will provide insights into the potential of this innovative approach to address long COVID symptoms.Read AnnouncementPublication - May 14,2025Publication Drug: HemopurifierAnnounced Date: May 14, 2025Indication: Severe COVID-19AnnouncementAethlon Medical, Inc. announced the publication (https://www.biorxiv.org/cgi/content/short/2025.05.09.652772v1) of a pre-clinical ex vivo study in pre-print vehicle bioRxiv, entitled, "Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device containing a Galanthus nivalis agglutinin (GNA) affinity resin."AI SummaryAethlon Medical, Inc. recently announced the publication of a pre-clinical ex vivo study on bioRxiv titled "Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device containing a Galanthus nivalis agglutinin (GNA) affinity resin." This study tested the Hemopurifier®, a blood filtration device that uses a proprietary GNA affinity resin to bind and remove platelet-derived extracellular vesicles (PD-EVs) from plasma. In the experiment, 200 milliliters of donated healthy human plasma was circulated through the device to simulate a clinical treatment session. The results showed that the Hemopurifier achieved a 98.5% removal of PD-EVs during a period equivalent to a four-hour treatment session. Researchers believe that the successful removal of these PD-EVs, which may contribute to conditions like cancer and other diseases, supports further investigation of the device across multiple medical indications.Read AnnouncementPublication - March 10,2025Publication Drug: HemopurifierAnnounced Date: March 10, 2025Indication: Severe COVID-19AnnouncementAethlon Medical, announced the publication of a pre-clinical study in the peer-reviewed journal Transplant Immunology (https://doi.org/10.1016/j.trim.2025.102215) on February 28, 2025, entitled, " A lectin affinity plasmapheresis device removes extracellular vesicles and microRNAs from renal perfusates following controlled oxygenated rewarming of discarded donor kidneys."AI SummaryAethlon Medical recently published a pre-clinical study in the peer-reviewed journal Transplant Immunology on February 28, 2025. The study, titled "A lectin affinity plasmapheresis device removes extracellular vesicles and microRNAs from renal perfusates following controlled oxygenated rewarming of discarded donor kidneys," focused on evaluating the Hemopurifier® in organ transplantation. Researchers demonstrated that when integrated into a machine perfusion circuit, the device significantly reduced extracellular vesicles and microRNAs in the perfusion fluid from donor kidneys. These harmful elements are believed to contribute to complications such as delayed function and rejection after kidney transplants. The promising results suggest that the Hemopurifier®, already explored for oncology and virology, may also improve the quality and function of retrieved kidneys. Further evaluation in clinical settings is planned to assess the potential benefits of this approach for enhancing organ preservation and transplant outcomes.Read AnnouncementProvided Update - December 20,2024Provided Update Drug: HemopurifierAnnounced Date: December 20, 2024Indication: Severe COVID-19AnnouncementAethlon Medical, Inc. today provided a statement of its investigational medical device with respect to H5N1 avian influenza "Bird Flu."AI SummaryAethlon Medical, Inc. today issued a statement regarding its investigational Hemopurifier device and its potential application against the H5N1 avian influenza, also known as Bird Flu. The Hemopurifier is an extracorporeal device designed to remove enveloped viruses and harmful particles like extracellular vesicles from the bloodstream. In laboratory tests conducted with Battelle labs, a scaled-down version of the device removed 99% of the H5N1 virus over six hours, suggesting it could provide a new avenue for treating severe influenza cases where standard treatments sometimes fail due to antiviral resistance. The company emphasized that while the Hemopurifier has been used safely in patients with other life-threatening illnesses such as hepatitis C, HIV, COVID-19, and Ebola, further monitoring and study will determine its effectiveness specifically for H5N1 infections.Read Announcement Aethlon Medical FDA Events - Frequently Asked Questions Has Aethlon Medical received FDA approval? As of now, Aethlon Medical (AEMD) has not received any FDA approvals for its therapy in the last two years. What drugs has Aethlon Medical submitted to the FDA? In the past two years, Aethlon Medical (AEMD) has reported FDA regulatory activity for Hemopurifier. What is the most recent FDA event for Aethlon Medical? The most recent FDA-related event for Aethlon Medical occurred on June 26, 2026, involving Hemopurifier. The update was categorized as "Publication," with the company reporting: "Aethlon Medical, Inc. announced publication of new peer-reviewed research in the International Journal of Molecular Sciences demonstrating that patients with Long COVID exhibit significantly increased levels of mannosylated extracellular vesicles (EVs) that can be captured using the same Galanthus nivalis agglutinin (GNA) affinity resin incorporated into the Company's Hemopurifier®." What conditions do Aethlon Medical's current drugs treat? Currently, Aethlon Medical has one therapy (Hemopurifier) targeting the following condition: Severe COVID-19. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Innate Pharma FDA EventsRecursion Pharmaceuticals FDA EventsSummit Therapeutics FDA EventsACADIA Pharmaceuticals FDA EventsBiogen FDA EventsEikon Therapeutics FDA EventsGain Therapeutics FDA EventsIonis Pharmaceuticals FDA EventsKaryopharm Therapeutics FDA EventsPulmonx FDA EventsMetaVia FDA EventsNeonc Technologies FDA EventsRegeneron Pharmaceuticals FDA EventsSELLAS Life Sciences Group FDA EventsSanofi FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies PAVmed FDA Events Sintx Technologies FDA Events SeaStar Medical FDA Events NeuroOne Medical Technologies FDA Events ENDRA Life Sciences FDA Events Bluejay Diagnostics FDA Events Beyond Air FDA Events Virax Biolabs Group FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:AEMD last updated on 6/26/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThis Could Be the Biggest Monetary Shift in 50 YearsThe U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trad...Patriot Gold Group | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aethlon Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aethlon Medical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Publication - June 26,2026Publication Drug: HemopurifierAnnounced Date: June 26, 2026Indication: Severe COVID-19AnnouncementAethlon Medical, Inc. announced publication of new peer-reviewed research in the International Journal of Molecular Sciences demonstrating that patients with Long COVID exhibit significantly increased levels of mannosylated extracellular vesicles (EVs) that can be captured using the same Galanthus nivalis agglutinin (GNA) affinity resin incorporated into the Company's Hemopurifier®.AI SummaryAethlon Medical said a new peer-reviewed study in the International Journal of Molecular Sciences adds scientific support for studying its Hemopurifier® in Long COVID. The research, done with investigators at the University of California, San Francisco, found that people with Long COVID have higher levels of altered extracellular vesicles, or EVs, in their blood. These EVs are tiny particles that can carry harmful material linked to disease. The company said the study showed these EVs are significantly mannosylated, meaning they display sugar patterns that can be targeted by Galanthus nivalis agglutinin, or GNA. That is important because the Hemopurifier uses the same GNA affinity resin to capture certain EVs and other disease-related particles. Aethlon said this creates a stronger scientific case for testing whether the device can remove harmful EVs and their cargo in Long COVID.Read Announcement
Provided Update - October 7,2025Provided Update Drug: HemopurifierAnnounced Date: October 7, 2025Indication: Severe COVID-19AnnouncementAethlon Medical, Inc today provided observations on the preliminary changes in extracellular vesicle (EV), microRNA and lymphocyte counts in the first patient cohort in its ongoing oncology clinical trial in Australia.AI SummaryAethlon Medical shared early observations from the first three patients in its ongoing Australian oncology trial using the Hemopurifier. After one four-hour treatment, two of the three patients showed decreases in large extracellular vesicles (EVs), including platelet-derived EVs. All three patients had drops in EVs carrying PD-L1, which can block T cells. In two patients, levels of seven out of ten cancer-related microRNAs fell temporarily, returning to baseline within one to three weeks. Blood tests also showed improved immune ratios, such as neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios, in at least two participants. Total T cell counts rose, including CD4, CD8 and tumor-specific (CD137+) cells, although timing varied. The company cautioned that these results are based on just three patients, one of whom withdrew after one week, involve only a single treatment, and use descriptive statistics. It is too early to know if these changes will recur with more treatments or lead to clinical benefits.Read Announcement
Abstract Presentation - June 9,2025Abstract Presentation Drug: HemopurifierAnnounced Date: June 9, 2025Indication: Severe COVID-19AnnouncementAethlon Medical, Inc announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel & Spa, Santa Fe, NM, United States, August 10-13,2025AI SummaryAethlon Medical, Inc. announced that an abstract on its Hemopurifier® Affinity Resin will be presented as a poster at the upcoming Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes. The event is scheduled to take place at the Eldorado Hotel & Spa in Santa Fe, NM, from August 10 to 13, 2025. The poster reviews the device’s ability to bind extracellular vesicles in blood samples from individuals suffering from long COVID, a condition with persistent symptoms following acute COVID-19. By using a proprietary lectin-based technology that targets mannosylated markers, the Hemopurifier® aims to remove these vesicles, which may contribute to ongoing health challenges. The presentation, set for August 12, 2025, will provide insights into the potential of this innovative approach to address long COVID symptoms.Read Announcement
Publication - May 14,2025Publication Drug: HemopurifierAnnounced Date: May 14, 2025Indication: Severe COVID-19AnnouncementAethlon Medical, Inc. announced the publication (https://www.biorxiv.org/cgi/content/short/2025.05.09.652772v1) of a pre-clinical ex vivo study in pre-print vehicle bioRxiv, entitled, "Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device containing a Galanthus nivalis agglutinin (GNA) affinity resin."AI SummaryAethlon Medical, Inc. recently announced the publication of a pre-clinical ex vivo study on bioRxiv titled "Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device containing a Galanthus nivalis agglutinin (GNA) affinity resin." This study tested the Hemopurifier®, a blood filtration device that uses a proprietary GNA affinity resin to bind and remove platelet-derived extracellular vesicles (PD-EVs) from plasma. In the experiment, 200 milliliters of donated healthy human plasma was circulated through the device to simulate a clinical treatment session. The results showed that the Hemopurifier achieved a 98.5% removal of PD-EVs during a period equivalent to a four-hour treatment session. Researchers believe that the successful removal of these PD-EVs, which may contribute to conditions like cancer and other diseases, supports further investigation of the device across multiple medical indications.Read Announcement
Publication - March 10,2025Publication Drug: HemopurifierAnnounced Date: March 10, 2025Indication: Severe COVID-19AnnouncementAethlon Medical, announced the publication of a pre-clinical study in the peer-reviewed journal Transplant Immunology (https://doi.org/10.1016/j.trim.2025.102215) on February 28, 2025, entitled, " A lectin affinity plasmapheresis device removes extracellular vesicles and microRNAs from renal perfusates following controlled oxygenated rewarming of discarded donor kidneys."AI SummaryAethlon Medical recently published a pre-clinical study in the peer-reviewed journal Transplant Immunology on February 28, 2025. The study, titled "A lectin affinity plasmapheresis device removes extracellular vesicles and microRNAs from renal perfusates following controlled oxygenated rewarming of discarded donor kidneys," focused on evaluating the Hemopurifier® in organ transplantation. Researchers demonstrated that when integrated into a machine perfusion circuit, the device significantly reduced extracellular vesicles and microRNAs in the perfusion fluid from donor kidneys. These harmful elements are believed to contribute to complications such as delayed function and rejection after kidney transplants. The promising results suggest that the Hemopurifier®, already explored for oncology and virology, may also improve the quality and function of retrieved kidneys. Further evaluation in clinical settings is planned to assess the potential benefits of this approach for enhancing organ preservation and transplant outcomes.Read Announcement
Provided Update - December 20,2024Provided Update Drug: HemopurifierAnnounced Date: December 20, 2024Indication: Severe COVID-19AnnouncementAethlon Medical, Inc. today provided a statement of its investigational medical device with respect to H5N1 avian influenza "Bird Flu."AI SummaryAethlon Medical, Inc. today issued a statement regarding its investigational Hemopurifier device and its potential application against the H5N1 avian influenza, also known as Bird Flu. The Hemopurifier is an extracorporeal device designed to remove enveloped viruses and harmful particles like extracellular vesicles from the bloodstream. In laboratory tests conducted with Battelle labs, a scaled-down version of the device removed 99% of the H5N1 virus over six hours, suggesting it could provide a new avenue for treating severe influenza cases where standard treatments sometimes fail due to antiviral resistance. The company emphasized that while the Hemopurifier has been used safely in patients with other life-threatening illnesses such as hepatitis C, HIV, COVID-19, and Ebola, further monitoring and study will determine its effectiveness specifically for H5N1 infections.Read Announcement